LIVE
ABBV
AbbVie Inc. · Healthcare
$216.49
+1.28% this month
VERSUS
⟷
COMPARE
LLY
Eli Lilly and Company · Healthcare
$1,098.57
+7.55% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
ABBV
2
LLY
3
Comparison scoreboard
LLY LEADS 3/5AI Score
ABBV 52.0
LLY ✓73.6
1Y Return
ABBV +16.72%
LLY ✓+38.84%
Fwd P/E
ABBV ✓14.01
LLY 25.47
Target Up.
ABBV ✓+11.34%
LLY +7.31%
Op. Margin
ABBV 32.16%
LLY ✓49.39%
Metrics last refreshed: 6/20/2026
Quick take
ABBV vs LLY Stock Comparison: AI Score, Valuation, Performance and Upside
AbbVie and Eli Lilly are both large pharmaceutical companies with strong drug franchises, but with opposite investment profiles. AbbVie is the income-focused pharma dividend aristocrat managing the Humira transition to Skyrizi and Rinvoq — slower growth, reliable dividends. Eli Lilly is the highest-growth large pharma in decades, powered by tirzepatide's GLP-1 obesity dominance — minimal dividend, maximum growth multiple. They serve different investor needs.
ABBV vs LLY is the premier pharma dividend aristocrat managing Humira's biosimilar erosion with Skyrizi/Rinvoq as succession drugs and Botox aesthetics adding consumer healthcare (AbbVie) versus the highest-growth large pharma in history with tirzepatide GLP-1 treating obesity as the largest drug market ever created (Eli Lilly) — income compounding through immunology franchise vs GLP-1 blockbuster growth multiple.
Live analysis · updated 6/20/2026
LLY holds the edge across 3 of 5 key metrics in this comparison. LLY has delivered stronger 1-year price return (+38.84% vs +16.72%), though ABBV trades at the lower forward P/E (14.01x vs 25.47x). LLY leads on both revenue growth (55.50%) and operating margin (49.39%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+11.34%) than for LLY (+7.31%).
Normalized 1Y performance
ABBV
LLY
Recent returns
ABBV
LLY
Analyst price targets & sentiment
ABBV · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$170.00
analyst mean$253.55
current price$216.49
+11.3% upside to analyst mean
LLY · 27 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.8/5.0)
Price target range
analyst low$650.00
analyst mean$1,215.79
current price$1,098.57
+7.3% upside to analyst mean
Who should consider this stock?
ABBV may suit investors who:
- →prefer the premier pharma dividend aristocrat with 50+ consecutive dividend increases and Skyrizi/Rinvoq successfully replacing Humira revenue post-biosimilar erosion
- →value AbbVie's diversified revenue across immunology (Skyrizi/Rinvoq), oncology (Imbruvica), and aesthetics (Botox) reducing single-drug pipeline dependence
- →want reliable pharmaceutical income from a company with demonstrated ability to manage major drug patent losses while maintaining dividend growth
- →are comfortable with Humira biosimilar ongoing revenue erosion, Rinvoq JAK inhibitor prescribing limitations, and need for continued pipeline development beyond current portfolio
LLY may suit investors who:
- →prefer the highest-growth large pharmaceutical company in decades as tirzepatide addresses obesity — a 650M-person global opportunity that dwarfs any prior drug market
- →value Eli Lilly's tirzepatide clinical differentiation (dual GIP/GLP-1, superior weight loss) creating sustainable market share vs Novo Nordisk's semaglutide
- →want transformational pharmaceutical growth multiple justified by GLP-1 market penetration potential as the obesity treatment market matures over the next decade
- →are comfortable with Lilly's premium valuation reflecting GLP-1 expectations, manufacturing capacity constraints, oral GLP-1 competition risk, and minimal current dividend yield
Performance & AI score
| Metric | ABBV | LLY |
|---|---|---|
| AI score | 52.0 | 73.6 |
| AI rank | #346 | #26 |
| Latest close | $216.49 | $1,098.57 |
| 1M return | +1.28% | +7.55% |
| 6M return | -3.49% | +5.45% |
| 1Y return | +16.72% | +38.84% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | LLY |
|---|---|---|
| 1Y ago | $11.67K (+16.7%) started 2025-06-18 | $13.99K (+39.9%) started 2025-06-18 |
| 5Y ago | $26.07K (+160.7%) started 2021-06-21 | $53.49K (+434.9%) started 2021-06-21 |
| 10Y ago | $83.39K (+733.9%) started 2016-06-20 | $206.62K (+1966.2%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | ABBV | LLY |
|---|---|---|
| Market cap | $402.35B | $1.01T |
| Trailing P/E | 111.09 | 40.32 |
| Forward P/E | 14.01 | 25.47 |
| Price/Sales | 5.85 | 14.10 |
| EV/Revenue | 7.42 | 14.51 |
| Analyst target | $253.55 | $1,215.79 |
| Target upside | +11.34% | +7.31% |
Growth, profitability & risk
| Metric | ABBV | LLY |
|---|---|---|
| Revenue growth | 12.40% | 55.50% |
| Earnings growth | -46.20% | 169.90% |
| EPS growth | -46.20% | +169.90% |
| FCF margin | +33.13% | +12.67% |
| Operating margin | 32.16% | 49.39% |
| Profit margin | 5.79% | 34.99% |
| ROIC proxy | 6225.00% | 107.46% |
| Return on equity | 6225.00% | 107.46% |
| Dividend yield | 3.04% | 0.61% |
| Beta | 0.31 | 0.52 |
| Debt/equity | 4789.60 | 139.01 |
| Current ratio | 0.80 | 1.50 |
| Quick ratio | 0.52 | 0.72 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
ABBV max drawdown19.23%
LLY max drawdown23.31%
ABBV max wkly drop8.49%
LLY max wkly drop17.93%
5Y risk snapshot
ABBV max drawdown21.92%
LLY max drawdown34.48%
ABBV max wkly drop17.30%
LLY max wkly drop17.93%
10Y risk snapshot
ABBV max drawdown45.09%
LLY max drawdown34.48%
ABBV max wkly drop19.39%
LLY max wkly drop17.93%
Performance metrics by period
| Period | Metric | ABBV | LLY |
|---|---|---|---|
| 1Y | Growth | +16.71% | +39.94% |
| CAGR | +16.74% | +40.01% | |
| Sharpe ratio | 0.57 | 0.96 | |
| Max drawdown | 19.23% | 23.31% | |
| Max daily drop | 5.20% | 14.14% | |
| Max wkly drop | 8.49% | 17.93% | |
| 5Y | Growth | +120.43% | +413.56% |
| CAGR | +17.16% | +38.78% | |
| Sharpe ratio | 0.61 | 1.04 | |
| Max drawdown | 21.92% | 34.48% | |
| Max daily drop | 12.57% | 14.14% | |
| Max wkly drop | 17.30% | 17.93% | |
| 10Y | Growth | +426.67% | +1649.40% |
| CAGR | +18.09% | +33.16% | |
| Sharpe ratio | 0.60 | 0.95 | |
| Max drawdown | 45.09% | 34.48% | |
| Max daily drop | 16.25% | 14.14% | |
| Max wkly drop | 19.39% | 17.93% |
Business comparison
| Category | ABBV | LLY |
|---|---|---|
| Company | AbbVie Inc. | Eli Lilly and Company |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | AbbVie is a biopharmaceutical company known for Humira (adalimumab — the world's best-selling drug for most of its history) for autoimmune diseases, and increasingly for its post-Humira portfolio: Skyrizi (IL-23 inhibitor for psoriasis/IBD) and Rinvoq (JAK inhibitor for RA, atopic dermatitis, and more). AbbVie also has Imbruvica (BTK inhibitor for blood cancers) and botox/aesthetics via Allergan. AbbVie is known as a premier dividend growth company having extended J&J's Dividend Aristocrat streak. | Eli Lilly is a pharmaceutical company experiencing extraordinary growth from its GLP-1 receptor agonist drugs for obesity (Zepbound/tirzepatide) and diabetes (Mounjaro/tirzepatide). Tirzepatide targets both GIP and GLP-1 receptors, producing superior weight loss vs semaglutide (Wegovy/Ozempic). Lilly also has Verzenio (breast cancer), Talvey (multiple myeloma), and a robust Alzheimer's pipeline including donanemab (Kisunla). Lilly is executing a massive manufacturing capacity expansion to meet GLP-1 demand. |
| Investor focus | Investors track Skyrizi and Rinvoq revenue growth as Humira replacements, Humira biosimilar erosion rate, Allergan aesthetics (Botox) performance, and AbbVie's dividend growth track record. | Investors track Mounjaro/Zepbound quarterly revenue and supply availability, GLP-1 market share vs Novo Nordisk's semaglutide, and manufacturing capacity expansion timeline. |
ABBV strengths
- →Skyrizi and Rinvoq are on track to collectively exceed Humira peak revenues — AbbVie's post-Humira portfolio transition appears more successful than many expected
- →Allergan acquisition added Botox aesthetics as a resilient premium consumer healthcare business with pricing power and global brand recognition
- →Exceptional dividend growth history — AbbVie has raised its dividend for 50+ consecutive years (including Abbott Labs years), one of the strongest dividend track records in pharma
LLY strengths
- →Tirzepatide's dual GIP/GLP-1 mechanism produces superior weight loss (~21% body weight) vs semaglutide (~15%) — clinical differentiation in the largest drug market opportunity in history
- →Obesity as a disease affects 650M+ people globally — even a small market penetration creates extraordinary revenue scale for Lilly's Zepbound
- →Verzenio CDK4/6 inhibitor growing strongly in breast cancer, Kisunla Alzheimer's approval provides additional non-obesity growth vectors
Risks to watch — ABBV
- →Humira biosimilar erosion is ongoing — multiple biosimilars are taking US market share, reducing Humira revenue that once drove 50%+ of AbbVie's total revenue
- →Rinvoq's JAK inhibitor class has FDA black box warning requirements that limit prescribing vs biologics — competing with Dupixent and other biologics
- →AbbVie's pipeline beyond Skyrizi/Rinvoq is less visible — investors need to see new pipeline assets to gain confidence in post-Skyrizi/Rinvoq long-term growth
Risks to watch — LLY
- →Lilly's valuation reflects enormous GLP-1 expectations — manufacturing capacity constraints and competition from Novo Nordisk and new entrants (oral GLP-1s, amgen, etc.) could disappoint
- →Manufacturing scale-up for tirzepatide is a multi-year constraint — supply shortages limit revenue relative to demand
- →Oral GLP-1 competition (semaglutide oral, orforglipron) could disrupt injectable GLP-1 demand if oral efficacy approaches injectable performance
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →